Exploring how serine metabolism affects aggressive types of acute myeloid leukemia
Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia
This study is looking at how certain cancer cells in aggressive types of acute myeloid leukemia (AML) use a substance called serine to grow, with the hope of finding new ways to treat this serious blood cancer in both adults and kids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11032874 on NIH RePORTER |
What this research studies
This research investigates the role of serine metabolism in aggressive sub-types of acute myeloid leukemia (AML), a severe blood cancer affecting both adults and children. The study aims to understand how AML cells utilize serine to support their growth and survival, potentially leading to new therapeutic strategies. By examining metabolic pathways and employing advanced techniques like metabolomics and proteomics, researchers hope to identify vulnerabilities in these cancer cells. The ultimate goal is to develop more effective treatments that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with aggressive sub-types of acute myeloid leukemia, particularly those with MLL-rearrangements or FLT3 internal tandem duplications.
Not a fit: Patients with less aggressive forms of leukemia or those who do not have the specific genetic markers being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates for patients with aggressive forms of acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could be effective for AML as well.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Sykes, Stephen Matthew — Washington University
- Study coordinator: Sykes, Stephen Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.